Collaboration in more than 46 countries.

You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.

NORTH AMERICA

Canada

United States

LATIN AMERICA

Argentina

Brazil

Mexico

Perú

GLOBAL

CEVA Global

EMEA (REGIONAL)

Denmark

Egypt

France

Germany

Hungary

Italy

Netherlands

Poland

Portugal

Romania

South Africa

Spain

Sweden

Tunisia

Turkey

Ukraine

United Kingdom

ASIA PACIFIC

Asia Pacific (Regional)

CHINA

India

Indonesia

Japan

Korea

Malaysia

Philippines

Share on:

Coxevac is granted authorization to be used in sheep

Ceva Santé Animale is proud to announce a significant expansion in the scope of  Coxevac’s marketing authorization within Europe, as it now includes sheep as a target species.

The impact of Q Fever on Sheep Health

Q Fever, a highly contagious zoonosis, poses a substantial threat and has a strong negative impact on the reproductive performance of ruminant farms.

Similar to cattle and goats, it causes a range of reproductive disorders in sheep, notably including abortions and stillbirths. An episode of Q Fever in a sheep flock can lead to the loss of 18% of lambs. Recent extensive studies in Portugal and Spain have revealed Coxiella burnetii as the second most frequently isolated pathogen responsible for sheep abortions. The ripple effect of Q Fever in the health of the sheep also causes significant economic losses in farms.

As a response to the control of Q Fever, Ceva has worked on several solutions to address this issue, resulting in the authorization of its effective vaccine, Coxevac, for sheep.

Coxevac: Q Fever Vaccine for Animals

Vaccination plays a pivotal role in managing and controlling Q fever. Coxevac, a unique phase I inactivated vaccine exclusively developed to combat Q Fever, has demonstrated its efficacy in reducing clinical signs and bacterial shedding in ruminants. Vaccination not only helps control the disease among animals but also minimizes the risk of transmission to humans.

Until recently, Coxevac was exclusively approved for use in cattle and goats. In response to the mounting demand from veterinarians working in the field, Ceva provided all the necessary studies to secure the European authorities’ approval for its use in sheep.

Philippe Gisbert, Ceva’s Ruminants Global Technical Manager, expressed the significance of this milestone, stating, “With this new claim for sheep we provide an efficient tool to control Q Fever. By adding the claim for cattle, goats and now sheep we cover the main reservoirs of the disease and we can help control the disease in humans.”

This expansion of Coxevac’s marketing authorization underscores Ceva’s unwavering dedication to be a key player in Q Fever control, firmly adhering to the One Health approach.

Watch the full interview about Q Fever with Philippe Gisbert, Ceva’s Ruminants Global Technical Manager, here.

This site is registered on wpml.org as a development site.